Hence, there is substantial interest in developing selective and potent NLRP3-targeted inhibitors for the treatment of CAPS and other diseases (Vande Walle & Lamkanfi, 2024). The gene discussed is NLRP3; the disease is cryopyrin-associated periodic syndrome.